6 October 2022 - For decades, academic clinical trials consortia have collaborated to optimise outcomes for childhood cancers through evaluating incremental improvements in conventional multimodality treatment regimes.
There are now increasing opportunities to partner with industry to test new medicines in academic-sponsored trials, but these collaborative studies rarely contribute to marketing authorisations.
We addressed why this is the case and sought solutions to enable academic-sponsored trials to directly contribute to the licensing of new medicines.